CLINICAL EXPERIENCE WITH PIRFENIDONE IN FIVE PATIENTS WITH SCLERODERMA-RELATED INTERSTITIAL LUNG DISEASE

被引：7

作者：

Miura, Yukiko ^{[1
,2
]}

Saito, Takefumi ^{[1
]}

Fujita, Kazutaka ^{[1
]}

Tsunoda, Yoshiya ^{[1
]}

Tanaka, Toru ^{[1
]}

Takoi, Hiroyuki ^{[1
]}

Yatagai, Yohei ^{[1
]}

Rin, Shigen ^{[1
]}

Sekine, Akimasa ^{[1
]}

Hayashihara, Kenji ^{[1
]}

Nei, Takahito ^{[2
]}

Azuma, Arata ^{[2
]}

机构：

[1] Natl Hosp Org, Ibarakihigashi Hosp, Dept Resp Med, Tokyo, Japan

[2] Nippon Med Sch, Dept Pulm Med & Oncol, Grad Sch Med, Tokyo, Japan

来源：

SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES | 2014年 / 31卷 / 03期

关键词：

Antifibrotic agent; interstitial lung disease; pirfenidone; scleroderma; vital capacity;

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Interstitial lung disease is the most common complication and cause of death among patients with scleroderma. Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. Herein, we report our clinical experience of administering pirfenidone, which is an antifibrotic agent, in five patients with scleroderma-related interstitial lung disease. All patients demonstrated an increase in vital capacity.

引用

页码：235 / 238

页数：4

共 50 条

[21] Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
Dinesh Khanna
Vivek Nagaraja
Chi-hong Tseng
Fereidoun Abtin
Robert Suh
Grace Kim
Athol Wells
Daniel E. Furst
Philip J. Clements
Michael D. Roth
Donald P. Tashkin
Jonathan Goldin
Arthritis Research & Therapy, 17
[22] Interstitial Lung Disease in Scleroderma
Schoenfeld, Sara R.
Castelino, Flavia V.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (02) : 237 - +
[23] Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease
Tzelepis, G. E.
Plastiras, S. C.
Karadimitrakis, S. P.
Vlachoylannopoulos, P. G.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (05) : 734 - 739
[24] Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice
Gonzalez-Sanchez, Elena
Munoz-Callejas, Antonio
Gomez-Roman, Javier
San Antonio, Esther
Marengo, Alessandro
Tsapis, Nicolas
Bohne-Japiassu, Kamila
Gonzalez-Tajuelo, Rafael
Pereda, Saray
Garcia-Perez, Javier
Cavagna, Lorenzo
Angel Gonzalez-Gay, Miguel
Francisca Vicente-Rabaneda, Esther
Meloni, Federica
Fattal, Elias
Castaneda, Santos
Urzainqui, Ana
BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (18) : 4534 - 4548
[25] An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Khanna, Dinesh
Albera, Carlo
Fischer, Aryeh
Khalidi, Nader
Raghu, Ganesh
Chung, Lorinda
Chen, Dan
Schiopu, Elena
Tagliaferri, Margit
Seibold, James R.
Gorina, Eduard
JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1672 - 1679
[26] New developments in scleroderma interstitial lung disease
Highland, KB
Silver, RM
CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) : 737 - 745
[27] Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials
Khanna, Dinesh
Nagaraja, Vivek
Tseng, Chi-hong
Abtin, Fereidoun
Suh, Robert
Kim, Grace
Wells, Athol
Furst, Daniel E.
Clements, Philip J.
Roth, Michael D.
Tashkin, Donald P.
Goldin, Jonathan
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[28] Clinically significant interstitial lung disease in limited scleroderma - Histopathology, clinical features, and survival
Fischer, Aryeh
Swigris, Jeffrey J.
Groshong, Steve D.
Cool, Carlyne D.
Sahin, Hakan
Lynch, David A.
Curran-Everett, Douglas
Gillis, JoAnn Z.
Meehan, Richard T.
Brown, Kevin K.
CHEST, 2008, 134 (03) : 601 - 605
[29] Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial
Nupoor Acharya
Shefali Khanna Sharma
Debashish Mishra
Sahajal Dhooria
Varun Dhir
Sanjay Jain
Rheumatology International, 2020, 40 : 703 - 710
[30] Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease
Katano, Takuma
Sekine, Akimasa
Ikeda, Satoshi
Yamakawa, Hideaki
Misumi, Toshihiro
Okabayashi, Hiroko
Okuda, Ryo
Kitamura, Hideya
Baba, Tomohisa
Komatsu, Shigeru
Hagiwara, Eri
Ogura, Takashi
RESPIRATORY INVESTIGATION, 2021, 59 (04) : 414 - 420

← 1 2 3 4 5 →